{"id":"cidofovir-intravenous","safety":{"commonSideEffects":[{"rate":"10-25","effect":"Nephrotoxicity / renal impairment"},{"rate":"15-20","effect":"Neutropenia"},{"rate":"10-15","effect":"Anemia"},{"rate":"10-15","effect":"Fever"},{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Ocular hypotony / vision loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cidofovir is a cytosine nucleotide analog that is phosphorylated intracellularly and then incorporated into viral DNA, causing chain termination and inhibiting viral DNA polymerase. It has broad-spectrum activity against DNA viruses including cytomegalovirus (CMV), herpesviruses, and other viral pathogens. The drug is particularly useful for treating infections in immunocompromised patients where conventional antivirals may be ineffective or resistance has developed.","oneSentence":"Cidofovir is a nucleotide analog that inhibits viral DNA polymerase, preventing viral DNA replication in infected cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:53.095Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cytomegalovirus (CMV) retinitis in immunocompromised patients"},{"name":"CMV and other viral infections in immunocompromised populations"}]},"trialDetails":[{"nctId":"NCT07387367","phase":"PHASE3","title":"A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT","status":"RECRUITING","sponsor":"SymBio Pharmaceuticals","startDate":"2026-02-15","conditions":"Adenovirus Infections","enrollment":180},{"nctId":"NCT04706923","phase":"PHASE2","title":"A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection","status":"RECRUITING","sponsor":"SymBio Pharmaceuticals","startDate":"2021-08-16","conditions":"Adenovirus Infections, Cytomegalovirus Infection","enrollment":52},{"nctId":"NCT03532035","phase":"PHASE2","title":"Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia","status":"WITHDRAWN","sponsor":"Jazz Pharmaceuticals","startDate":"2018-12-15","conditions":"Adenovirus","enrollment":""},{"nctId":"NCT00000143","phase":"PHASE3","title":"Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"1997-05","conditions":"Cytomegalovirus Retinitis, HIV Infections","enrollment":61},{"nctId":"NCT00138424","phase":"PHASE1, PHASE2","title":"Cidofovir in Renal Transplant Recipients With BKVN","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-05","conditions":"BK Virus (Nephropathy)","enrollment":22},{"nctId":"NCT00000894","phase":"PHASE4","title":"Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Cytomegalovirus Retinitis, HIV Infections","enrollment":300},{"nctId":"NCT00002384","phase":"NA","title":"A Study of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS","status":"UNKNOWN","sponsor":"Gilead Sciences","startDate":"","conditions":"Cytomegalovirus Retinitis, HIV Infections","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vistide"],"phase":"phase_3","status":"active","brandName":"Cidofovir intravenous","genericName":"Cidofovir intravenous","companyName":"Johns Hopkins Bloomberg School of Public Health","companyId":"johns-hopkins-bloomberg-school-of-public-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cidofovir is a nucleotide analog that inhibits viral DNA polymerase, preventing viral DNA replication in infected cells. Used for Cytomegalovirus (CMV) retinitis in immunocompromised patients, CMV and other viral infections in immunocompromised populations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}